Summary: A double-blind crossover placebo controlled study was performed on 20 patients with stable chronic asthma, in order to obtain dose response data to ipratropium bromide (40, 80, 200 
Introduction
Ipratropium bromide is widely used for the treatment of asthma and chronic airflow obstruction.
The standard dose of 40 fg administered by metered dose inhaler has been shown to be effective in these diseases.-3 It has also been used in a nebulised form4-6 and in combination with P2 agonists.7'8 More recent work has suggested that a greater and more prolonged response may be produced with higher doses.i'49 This study was intended to determine the dose response to ipratropium bromide and the clinical acceptability and benefit of higher than standard therapeutic doses.
Materials and methods
Twenty chronic stable asthmatics (4 male) took part in this study ( 
